Quantum Biopharma Ltd.

BRIEF

published on 12/20/2024 at 15:20, 3 months 24 days ago

Quantum BioPharma Embraces Cryptocurrency for Treasury Diversification

Financial Compliance Strategic Diversification Quantum BioPharma Bitcoin Treasury Cryptocurrency Investment
PRESS RELEASE

published on 12/20/2024 at 15:15, 3 months 24 days ago

Quantum Biopharma Diversifies Treasury With the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency
Quantum BioPharma Ltd. purchases $1,000,000 Bitcoin and other cryptocurrencies, allows cryptocurrency transactions, emphasizing compliance and potential returns for shareholders

Bitcoin Compliance Investment Cryptocurrency Quantum BioPharma
BRIEF

published on 12/14/2024 at 01:05, 4 months ago

Quantum BioPharma Concludes Initial Tranche of Offering

First Tranche Capital Development Quantum BioPharma Canadian Dollars Debenture Units
PRESS RELEASE

published on 12/14/2024 at 01:00, 4 months ago

Quantum Biopharma Announces Closing of First Tranche
Quantum BioPharma closes initial tranche of offering, issuing 500 Debenture Units for $500,000. Proceeds for business development and working capital. Securities subject to statutory hold period

Working Capital Statutory Hold Period Quantum BioPharma Debenture Units Tranche Offering
BRIEF

published on 12/10/2024 at 13:35, 4 months 4 days ago

Quantum Biopharma Moves Forward in Lucid-MS Clinical Trial

Biopharmaceutical Research Quantum BioPharma Lucid-MS Trial Clinical Advancement Safety Review
PRESS RELEASE

published on 12/10/2024 at 13:30, 4 months 4 days ago

Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS)
Quantum BioPharma announces approval to proceed with dosing of second cohort in Lucid-21-302 trial. Company focused on innovative treatments for neurodegenerative disorders

Drug Development Neurodegenerative Disorders Quantum BioPharma Lucid-21-302 Trial Safety Review Committee
BRIEF

published on 12/05/2024 at 13:35, 4 months 9 days ago

Quantum BioPharma Launches Private Placement for $5 Million

Private Placement Convertible Debenture Canadian Market Investment Offering Quantum BioPharma
PRESS RELEASE

published on 12/05/2024 at 13:30, 4 months 9 days ago

Quantum Biopharma Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million
Quantum BioPharma announces a non-brokered private placement offering of convertible debenture units. Proceeds for business development and working capital

Private Placement Working Capital Business Development Quantum BioPharma Debenture Units
BRIEF

published on 11/25/2024 at 13:05, 4 months 19 days ago

Quantum BioPharma Seeks Shareholder Support in $700M Alleged Manipulation Case

Legal Action Market Manipulation Quantum BioPharma Shareholder Involvement $700M Lawsuit
PRESS RELEASE

published on 11/25/2024 at 13:00, 4 months 19 days ago

Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price
Quantum BioPharma Ltd. seeks justice against alleged market manipulation, assembling legal teams to claim damages. Shareholders invited to join combined pursuit for justice against the Defendants

Shareholders Lawsuit Market Manipulation Quantum BioPharma Ltd. Legal Teams

Published on 04/14/2025 at 14:30, 11 minutes ago

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
Published on 04/14/2025 at 14:30, 11 minutes ago

Pathfinder Signs Letter of Intent to Acquire 40% Interest in Company Developing Okanagan Modular Home Community
Published on 04/14/2025 at 14:00, 41 minutes ago

Zentek Announce Strategic Partnership with Filtration Solutions Industrial Co. to Manufacture and Distribute Graphene-Enhanced HVAC Filters
Published on 04/14/2025 at 13:30, 1 hour 11 minutes ago

Condor Resources Announces Life Offering Private Placement of Up to $1.5 Million
Published on 04/14/2025 at 13:00, 1 hour 41 minutes ago

Honey Badger Silver Appoints Williams Executive Chairman and Interim CEO

View all ACCESSWIRE

Published on 04/14/2025 at 14:25, 16 minutes ago

CSDS RNS CFTN - Staking Rewards Update (14/04/25)
Published on 04/14/2025 at 14:00, 41 minutes ago

GEA successfully completes share buyback program
Published on 04/14/2025 at 13:51, 49 minutes ago

Custodian Property Income REIT plc: Interim dividend
Published on 04/14/2025 at 13:09, 1 hour 32 minutes ago

Original-Research: Knaus Tabbert AG (von First Berlin Equity Research GmbH): Kaufen
Published on 04/14/2025 at 12:15, 2 hours 25 minutes ago

Net Asset Value(s)

View all EQS

Published on 04/14/2025 at 08:15, 6 hours 26 minutes ago

Aéroports de Paris SA - Filing of the 2024 Universal Registration Document
Published on 04/11/2025 at 18:30, 2 days 20 hours ago

Reclassification of shares within the Feuillet family concert with no impact on the control of the company
Published on 04/11/2025 at 18:00, 2 days 20 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/03/2025
Published on 04/11/2025 at 17:45, 2 days 20 hours ago

NFL Biosciences presents its 2024 annual results and provides an update on its clinical program
Published on 04/11/2025 at 13:49, 3 days ago

Statement about the number of shares composing the share capital and the number of voting rights as at March 31, 2025

View all LES ECHOS COMFI WIRE

News